Back

Stabilizers of transthyretin in amyloid cardiomyopathy: a systematic review and meta-analysis.

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease 1 Clinical HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Ms Lucrecia Maria Burgos

Instituto Cardiovascular De Buenos Aires, Buenos Aires (Argentina)

5 More presentations in this session

Presentation thumbnail
SGLT2 inhibitors in wild-type transthyretin amyloid cardiomyopathy: what to expect?
Doctor L. Pinheiro (Guimaraes, PT)
Abstract Slides Video
Presentation thumbnail
Therapeutic value of spironolactone in wild-type transthyretin amyloid cardiomyopathy
Doctor L. Pinheiro (Guimaraes, PT)
Abstract Slides Video
Presentation thumbnail
Improving survival rates of patients with light-chain cardiac amyloidosis in recent years
Doctor T. Nabeta (Sagamihara, JP)
Abstract Slides Video
Presentation thumbnail
Incidence and progression of left ventricular involvement in patients with arrythmogenic cardiomyopathy
Doctor A. Diaz Exposito (Malaga, ES)
Abstract Slides Video
Presentation thumbnail
Left ventricular non compaction in sub-saharan african adults
Doctor N. GAYE (Dakar, SN)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in myocardial disease 1

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Transthyretin stabiliser therapy in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis
thumbnail
Congress Presentation
Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM
thumbnail
Congress Presentation
Effects of targeted transthyretin amyloid cardiomyopathy treatments on clinical outcomes a meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources